<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152633</url>
  </required_header>
  <id_info>
    <org_study_id>Retina-Losartan</org_study_id>
    <nct_id>NCT00152633</nct_id>
  </id_info>
  <brief_title>Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension</brief_title>
  <official_title>Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Essential hypertension is commonly associated with impaired endothelial function. The retinal
      vasculature is morphologically and functionally related to the cerebral vessels because of
      the common origin from the internal carotid artery. A recent study in hypertensive patients
      demonstrated that endothelial function of the retinal vasculature is impaired in hypertensive
      patients and that it can be restored by treatment with an AT1-receptor antagonist. It is not
      clear whether this effect is due to blood pressure lowering or whether this is a blood
      pressure independent effect. The present randomized, double blind study with a cross over
      design addresses this issue by comparing the effects of losartan and metoprolol on retinal
      endothelial function in patients with essential hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patient could be recruited.
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in retinal endothelial function</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Losartan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betablocker</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Metoprolol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <arm_group_label>Betablocker</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Treatment with Losartan</description>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged 18-65 years with essential hypertension

        Exclusion Criteria:

          -  Secondary forms of hypertension

          -  Advanced damage of vital organs (grade III and IV retinopathy)

          -  History of serious hypersensitivity reaction to AT1-receptor blockers

          -  Actual or anamnestic alcohol- or drug abuse.

          -  Smokers or ex-smokers &lt; 1 year.

          -  Patients with Diabetes mellitus (oral medication or insulin).

          -  Patients with arterial fibrillation or AV-Block (II° or more).

          -  Patients with anamnestic myocardial infarction.

          -  Patients with instable angina pectoris including EcG-aberrations or cardiac
             insufficiency NYHA III or IV.

          -  History of malignancy (unless a documented disease-free period exceeding 10 years is
             present) with teh exception of basal cell carcinoma of the skin

          -  History of allograft transplantation

          -  Therapy with not approved concomitant medication, or participation in a clinical study
             within 4 weeks preceding treatment start.

          -  Disease which interfere with the pharmacodynamics and pharmacokinetics of the study
             drug.

          -  Liver-or kidney disease with SGOT, GPT, g-GT, AP, bilirubin and creatinin or above
             200% of standard.

          -  Patients, who are not sufficiently compliant, or patients, who are not capable or
             willing to appear for controlling vistas.

          -  Presumed risk of transmission of HIV or hepatitis via blood from the participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland E Schmieder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRC, Med. Klinik 4, University of Erlangen-Nürnberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRC, Med. Klinik 4, University of Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>July 4, 2012</last_update_submitted>
  <last_update_submitted_qc>July 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Erlangen-Nürnberg Medical School</investigator_affiliation>
    <investigator_full_name>Roland E. Schmieder</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>endothelium, hypertension, retina, AT1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

